With just a few days until the Commission publishes both its Industrial Strategy and the roadmap for the upcoming Pharmaceutical Strategy, the future of Europe’s life sciences sector is in sharp focus.
The publication of both documents is eagerly anticipated. Much rests on their content; for patients across Europe, for the European economy and Europe’s life science community.
In the midst of a coronavirus epidemic, attention turns to the research-based industry to rapidly develop diagnostics, vaccines and treatments in response to such a significant public health threat. It underlines the need for an infrastructure and policy environment that supports medical research in Europe.
Read more
Do you have a Connecting Healthcare story to tell?
ENISA organises the 5th edition of Cyber Europe, the largest Pan European Cybersecurity Exercise, focusing on the healthcare...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.